4-MONTH MONITORING STUDY TO EVALUATE THE RATE OF NASAL POLYPOSIS IN SUBJECTS WHICH IMPROVED WITH UP TO 4 MONTHS OF TREATMENT WITH MOMETHASONE FUROATE IN NASAL OR PLACEBO AEROSOL IN STUDY P01925
Not Applicable
- Conditions
- -J33J33
- Registration Number
- PER-034-02
- Lead Sponsor
- SCHERING PLOUGH RESEARCH INSTITUTE,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
The subjects must present an improvement with the treatment of the Study PCI 925 and be able to join immediately.
The subjects must not have experienced an important change in their clinical history or in the concomitant medication used, which could make the evaluations of this study impossible.
Exclusion Criteria
Women who intend to become pregnant or who are pregnant
find breastfeeding, or are not using a medically acceptable contraceptive.
Subjects who use concomitant medications that motivate their exclusion.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <br>Outcome name:Recurrence of the presence of nasal polyposis<br>Measure:The recurrence of nasal polyposis after the treatment of Study P01925 will be evaluated by the change in the size of the polyps and in the congestion score, from the beginning of Study P02573 until the end of Study P02573.<br>Timepoints:4 month<br>
- Secondary Outcome Measures
Name Time Method <br>Outcome name:not contemplated<br>Measure:not contemplated<br>Timepoints:not contemplated<br>